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Background: Hypoxic-ischemic injury is thought to play a significant role in necrotizing enterocolitis (NEC). Nitric
Oxide (NO) is the principal inhibitory neurotransmitter in the gut and is involved in regulation of mucosal blood
flow and maintenance of mucosal integrity. NO is synthesized from L-arginine by NO synthases. Our primary objective
was to determine the effectiveness of supplemental L-arginine versus placebo in prevention of NEC in preterm
infants ≤ 34 weeks gestational age by systematic review of published randomized controlled trials (RCTs).
Methods: This review included RCTs in which L-arginine was administered as a supplement to neonates to prevent
NEC. Searches were conducted in OVID MEDLINE, EMBASE, PubMed, and CINAHL from their dates of inception to July,
2014. Inclusion criteria were informed parental consent, neonates born at ≤ 34 weeks gestation, and birth weight ≤
1500 g. Exclusion criteria included neonates with severe congenital anomalies and inborn errors of metabolism.
Incidence of NEC was the primary outcome measure. Whole data were analyzed by RevMan 5.1 (Update Software,
Oxford, UK). Outcome data were analyzed to determine risk ratios, number needed to treat, confidence intervals, and
test for overall effect.
Results: Two trials including 425 neonates were eligible for this review. Of these, 235 neonates were included in the
study. L-arginine had a 59% reduction in the incidence of stage II and III NEC (RR 0.41, 95% CI 0.20 to 0.85, NNT = 9)
compared with placebo (P = 0.02). A similar finding was identified for all stages of NEC (60% reduction, RR 0.40, 95%
CI 0.23 to 0.69, NNT = 5) (P = 0.001). At age 3 yrs, there was no significant difference between the 2 groups in terms
of any neurodevelopmental disability (RR 0.65; 95% CI 0.23-1.83, P = 0.41).
Conclusions: L-arginine supplementation appears to be protective in prevention of NEC in preterm infants and
without any significant impact on neurodevelopmental outcomes at 36 months of corrected age. With the addition of
the results of one more study to the literature, an intriguing role for L-arginine supplementation continues to gain
support. However, large multi-centre RCTs are needed before this can become common practice.
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Necrotizing enterocolitis (NEC) is the most common ac-
quired gastrointestinal emergency in premature infants.
It is characterized by ischemic necrosis of the intestinal
mucosa, inflammation, invasion of enteric gas-forming
organisms, and dissection of gas into the muscularis and* Correspondence: aklodha@ucalgary.ca
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unless otherwise stated.portal venous system [1]. NEC occurs in 1–3 per 1000
live births and 1–7.7% of admissions to neonatal inten-
sive care units (NICU) [2]. The mortality of NEC varies
based on the birth weight of the affected infant and the
NEC Stage (I, II, III) and ranges from 20-30%, with the
greatest mortality among infants requiring surgical inter-
vention [3,4]. The pathogenesis of NEC remains elusive;
however, it is likely the result of a multifactorial process
in a susceptible host. Of particular interest is the role
played by intestinal vascular resistance in the develop-
ment of NEC [5-7]. Hypoxic-ischemic injury is thoughtl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Mitchell et al. BMC Pediatrics 2014, 14:226 Page 2 of 10
http://www.biomedcentral.com/1471-2431/14/226to play a significant role [8]. Mesenteric blood flow in
neonates may decline in the presence of extreme hyp-
oxia and severe abdominal distension [9,10]. The result-
ing increased mesenteric vascular resistance can lead to
reduced intestinal oxygen extraction and subsequent
mesenteric acidemia [9]. Mucosal injury is seen initially,
which may result in mucosal necrosis with ulceration
and tissue sloughing [8]. Reperfusion-induced tissue
damage after a hypoxic-ischemic event can produce on-
going injury to the intestinal mucosa via cytotoxic vas-
cular endothelial cell damage and cytotoxic effects on
cells of oxygen free radicals [8,11-15]. NEC is a complex
and multifactorial disease. Various clinical studies re-
vealed that inflammatory mediators especially TNFα,Figure 1 Study selection for systematic review.IL-1, platelet activating factor, and nitric oxide (NO),
produced by enterocytes and macrophages may play a
role in the pathogenesis of NEC [16].
Nitric oxide (NO) plays an important role in maintain-
ing baseline vasodilator tone [17]. It is the principal in-
hibitory neurotransmitter in the gastrointestinal system
inducing gut smooth muscle relaxation, and helps regu-
late mucosal blood flow, maintenance of mucosal integ-
rity, and intestinal barrier function [18-20]. A number of
animal model studies of bowel injury have demonstrated
that inhibition of NO increases the area of intestinal
damage [5,20-24]. NO is synthesized from the amino
acid L-arginine by NO synthases (NOS) [17,25]. Con-
tinuous intravenous infusion with L-arginine markedly
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[26]. Plasma arginine concentrations are decreased in
premature infants with NEC [27,28].
A Cochrane review of the role of L-arginine based on
one study showed a reduction of NEC in premature neo-
nates [29]. However, due to the small number of neo-
nates in that study and without further evidence from
other RCTs, the role of prophylactic L-arginine did not
become a common practice in modern NICUs [30].
There is one more study published since the previous re-
view [31]. The primary objective of this systematic re-
view was to use all available data, including those from
recently published randomized trials, to evaluate the ef-
fectiveness of supplemental L-arginine versus placebo in
the prevention of necrotizing enterocolitis in preterm
infants.Table 1 Characteristics of included studies






Total 254 infants eligible for the
study
Total 152 enrolled
Masking of allocation – Yes Total 150 infants followed up, 1
died before commencing the
study supplement, 1 was
removed for IVH Grade ≥2




Excluded patients with severe
congenital anomalies, congenital
non-bacterial infection, evidence
of IVH Grade ≥2 on cranial
ultrasound by day 3 of life,
conjugated hyperbilirubinemia,
evidence of an inborn error of
metabolism, exchange transfusio




Inclusion criteria – birth weight






Total 171 infants eligible for the s
Masking of allocation – Yes Total 83 enrolled
Masking of intervention –
Yes
Total 83 infants followed up
Masking of outcome
assessment – Yes
Excluded patients with severe




Did not exclude patients with
IVH Grade Stage ≥ 2
Inclusion criteria – birth weight ≤
1500 g and gestational age ≤
34 weeks
Abbreviations: IVH intraventricular hemorrhage, NEC necrotizing enterocolitis, NG NaMethods
The search strategy of the Cochrane Neonatal Review
Group was used. The systematic review reporting fol-
lows the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) [32].
Search strategy for identification of studies
Searches were conducted in OVID MEDLINE, EMBASE,
PubMed, and CINAHL from their date of inception to
July 14, 2014, restricted to English language and human
studies. The search strategy was developed jointly by the
lead investigator (AKL) and a medical librarian (HLR)
for OVID MEDLINE using exploded MeSH terms and
keywords for premature infants, necrotizing enterocoli-
tis, and L-arginine. This strategy was translated for
EMBASE, PubMed, and CINAHL (HLR). Trials in whichInterventions Outcomes Allocation
concealment
Study group: 1.5 mmol/kg per
day L-arginine added to TPN.




– NEC, all stages
Adequate
Control group: normal saline
(same volume)
n
tudy Study group: 1.5 mmol/kg
per day liquid BID with NG





Control group: 5% glucose in
equivalent volume
sogastric, TFI total fluid intake, TPN total parenteral nutrition.
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prevent NEC in preterm neonates were included. Refer-
ences from previous reviews were also examined. All
studies published in the English language were included
in the study.
Search strategy: Controlled vocabulary (MeSH terms),
keywords, and text words used: Infant, premature; nec-
rotizing enterocolitis; L-arginine; neonatal intensive care;
neonatal intensive care units; neonate. We identified
relevant studies also by citation tracking. Experts in the
field were also contacted to improve the search strategy.
(Additional file 1).
Eligibility criteria
Randomized controlled trials that compared L-arginine
to control or placebo to use as a prophylactic agent to
prevent NEC were included. Criteria for subject inclu-
sion included neonates born at ≤ 34 weeks’ gestation,
and with birth weight ≤ 1500 g. Exclusion criteria in-
cluded neonates with severe congenital anomalies and
inborn errors of metabolism. The selection of relevant
studies was by consensus.
Study identification and data extraction
All abstracts and published studies were independently
identified and assessed for inclusion by two reviewers
(KM, AL). Full papers were retrieved and checked for in-
clusion criteria. Each reviewer separately extracted dataTable 2 Demographic data of enrolled neonates*
L-arginine group
Amin et al. N = 75 Polycar
Male sex, n (%) 46 (61) 17 (42.5
Birth weight, g, mean 952 1168
Gestational age, wk, mean 27.4 29.2
Caesarian section, n (%) ND 30 (75)
Vaginal delivery, n (%) ND 10 (25)
IUGR, n (%) 5 (7) 16 (40)
Maternal antibiotics during labor, n (%) 45 (60) 14 (35)
Breast milk, n (%) ND 7 (17.5)
Preterm formula, n (%) ND 33 (82.5
Apgar score at 5 minutes, median 8 8
Antenatal steroids, n (%) 66 (88) 32 (80)
IVH at study entry grade <2 9 (12) ND
Postnatal steroids, n (%) 23 (31) ND
Hypotension after birth, n (%) 30(40) ND
Umbilical arterial cord pH, median 7.25 ND
Umbilical arterial cord Base excess −4.3 ND
Umbilical artery catheter, n (%) 50 (67) ND
Values are presented as No. (%) unless otherwise indicated, *P-values = Non-signific
Abbreviations: IUGR Intrauterine growth restriction, IVH Intraventricular hemorrhage,using the standardized Neonatal Cochrane group data
abstraction forms. A third reviewer (HS) entered data
into RevMan 5.1 (Update Software, Oxford, UK) and an-
other reviewer cross-checked the printout against his/
her data abstraction forms. The information was com-
pared and all differences were resolved by consensus.
Methodological quality
The methodological quality of the studies was assessed
by two reviewers using the risk of bias assessment tool as
endorsed by the Cochrane Neonatal Review Group and
van Tulder’s guidelines [33]. The Cochrane Neonatal Re-
view Group assessment included sequence generation, al-
location concealment, blinding of outcome assessment,
completeness of assessment, selective reporting bias and
likelihood of other biases. van Tulder’s instrument is de-
signed to assess internal validity of clinical trials and
should include 11 items. Trials fulfilling six or more
items were considered to be of high quality.
Outcome measures
The incidence of all stages of NEC was the primary out-
come measure. Secondary outcomes measured were
stages II and III NEC, mortality in patients with NEC,
incidence of respiratory distress syndrome (RDS), inci-
dence of intraventricular hemorrhage (IVH), and neuro-
developmental outcomes at 36 months of corrected age.
Neurodevelopmental disabilities were considered presentPlacebo group
pou et al. N = 40 Amin et al. N = 77 Polycarpou et al. N = 43





7 (9) 14 (32.6)
50 (65) 18 (42)
ND 5 (11.6)
) ND 38 (88.4)
7 8









Figure 2 Funnel plot to assess publication bias. Each circle
represents one study. Publication bias was not detected.
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blindness or deafness.
Cerebral palsy: (CP) refers to a non-progressive dis-
ability of movement and posture and was diagnosed on
the basis of abnormal muscle tone and reflexes on the
physical and neurological examination.
Cognitive Delay: Delayed cognitive function was diag-
nosed if there was a cognitive score >2 SD below the
mean on age-appropriate standardized testing.
Blindness: Considered present if the infants had bilat-
eral blindness with corrected visual acuity of <20/200 in
the better eye.
Deafness: Defined as a bilateral sensorineural loss
requiring amplification.Statistical analysis
The whole data were analyzed with Review Manager
software (RevMan 5.1; Cochrane Centre) using Mantel-
Haenszel method and fixed-effect model. Statistical ana-
lysis included relative risk ratios (RRs), number needed
to treat (NNT) for dichotomous outcomes and weighted
mean difference (WMD) for continuous outcomes. All
estimates of treatment effects were reported with 95%
confidence intervals (CI). Heterogeneity was assessedFigure 3 L-arginine supplementation prevents stage II and III necrotizusing a χ2-test and P-values lower than 0.05 were inter-
preted as being statistically significant.
Results
Twenty-one studies were identified as being potentially
relevant to this systematic review (Figure 1). Seventeen
studies were excluded as they did not meet all the inclu-
sion criteria. Two of the remaining four studies were
systematic reviews by the same author but published in
different versions of the Cochrane library based on one
randomized, controlled trial without any revision. The
remaining two studies were analyzed and data were
compiled (Table 1).
Methodological quality of included studies
One study scored 11 on the van Tulder qualitative as-
sessment instrument and the other study scored 10,
therefore, both were high quality studies (Table 1) [30,31].
Two studies were included in the final analysis
(Table 1). The efficacy of prophylactic L-arginine supple-
mentation to prevent necrotizing enterocolitis in neo-
nates was studied in both trials. One study administered
L-arginine intravenously until enteral feeds reached a
predetermined level of the total daily fluid intake, after
which point L-arginine was supplemented enterally,
while the other focused solely on enteral L-arginine ad-
ministration [30,31]. The number of patients varied be-
tween the studies; however, the follow-up period was the
same. The patients’ characteristics were similar in both
treatment and control groups (Table 2). The funnel plot
is shown in Figure 2. This plot did not show any publi-
cation bias.
The meta-analysis of the trials revealed that neonates
who had received prophylactic supplemental L-arginine
had a 59% reduction in the incidence of stage II and III
NEC (RR 0.41, 95% CI 0.20 to 0.85; I2 = 0%) compared
with placebo (P = 0.02) (Figure 3) and NNT was 9. Stat-
istical significance was also present when comparing the
L-arginine-supplemented group and the placebo group
with respect to incidence of all stages of NEC (Figure 4)
and NNT was 5. A 60% reduction in the incidence of
NEC was noted in the L-arginine supplemented group
(RR 0.40, 95% CI 0.23 to 0.69; I2 = 59%) (P = 0.001).ing enterocolitis in premature infants.
Figure 4 L-arginine supplementation prevents necrotizing enterocolitis (all stages) in premature infants.
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III and IV (Figure 5) (RR 0.85, 95% CI 0.43 to 1.68, P =
0.64) and respiratory distress syndrome (Figure 6) (RR
0.96, 95% CI 0.81 to 1.13, P = 0.63) were not statistically
significant between groups (Table 3). Mortality due to
NEC was also not statistically significant. Neurodevelop-
mental outcomes are shown in Figure 7.
Discussion
The analysis of this updated systematic review of the
RCTs conducted in premature infants receiving L-
arginine as a prophylactic agent for prevention of NEC
showed a statistically significant reduction in the inci-
dence of stage II and III NEC (P = 0.02) (NNT = 9) and
all stages of NEC (P = 0.001) (NNT = 5) in preterm in-
fants supplemented with L-arginine compared to those
in the placebo group. Given the NNT for both stage II
and III NEC and all stages of NEC, this certainly makes
the prospect of L-arginine having a role in the routine
care of premature neonates an interesting one. In
addition, with the absence of significant side effects and
a reduction in both medical and surgical NEC, L-
arginine may have a prominent role in upcoming years.
Our results demonstrate a statistically significant re-
duction in the incidence of stage II and III NEC. This
was initially suggested by Amin et al.; however, did not
reach statistical significance (P = 0.077) [30]. The results
from Polycarpou et al. were also non-significant [31].
The significant P-value that was found in our study is
likely in large part due to the increased proportion of
cases of stage III NEC in Polycarpou et al. compared toFigure 5 Supplementation with L-arginine to prevent necrotizing ent
difference on intraventricular hemorrhage incidence between study gAmin et al. and the larger sample size achieved from
pooling the studies. As such, our results support Amin
et al.’s previous findings that were suggestive of a reduc-
tion in the incidence of NEC [30]. Polycarpou et al.’s
study did not show statistical significance for all stages
of NEC, but did note a statistically significant reduction
in the incidence of stage III NEC [31].
There were no statistically significant differences be-
tween both groups with respect to secondary outcomes
(Table 3). Regarding IVH, Polycarpou et al. did not ex-
clude neonates with IVH grades III and IV, as they were
in Amin et al.’s study [31,30]. As such, a prominent dif-
ference was noted in the proportion of infants with
grades III and IV IVH when data were compared: 4% of
Amin et al.’s total sample vs. 25% of Polycarpou et al.’s
total sample [30,31]. When the data were combined and
compared against placebo, a statistically significant dif-
ference was not found (P = 0.64).
We demonstrate in our systematic review that L-
arginine supplemented infants in one RCT for preven-
tion of NEC did not have any difference in the long term
neurodevelopmental outcomes at the age of 36 months
of corrected age compared with those who received pla-
cebo [34].
NO plays a key role in intestinal epithelial injury in NEC.
Ford and his co-investigators have established the role of
iNOS-derived NO in NEC and also found an upregulation
of iNOS mRNA and protein in infants undergoing laparot-
omy for NEC, as compared to infants those were undergo-
ing for resection of intestine due to other reasons [6]. NO
is an endothelial-derived relaxing factor – a potent, short-erocolitis in premature infants has no statistically significant
roups.
Figure 6 Supplementation with L-arginine to prevent necrotizing enterocolitis in premature infants has no statistically significant
difference on respiratory distress syndrome incidence between study groups.
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processes including tissue homeostasis, neurotransmission,
and inflammation. Nitric oxide is a product of NO syn-
thase (NOS) which converts arginine and oxygen into NO
and citrulline. There are three isomers of NOS and each
coded by different genes. Endothelial NOS (eNOS) and
neuronal NOS (nNOS) isoforms are expressed at low levels
and these enzymes produce a small amount of NO. Both
of these isoforms are activated by calmodulin. The third
isoform is calcium-independent and is known as inducible
NOS (iNOS) and binds to calmodulin with a very good af-
finity. iNOS isoforms are produced at high levels during
periods of inflammation. During expression of iNOS, there
is further production of NO in nanomolar to micromolar
concentrations. The reaction of NO with superoxide leads
to the production of peroxynitrite, a potent oxidant. These
molecules further lead to cytopathic effects and result in
enterocyte apoptosis or necrosis, impairment of enterocyte
proliferation, and epithelium restitution through enterocyte
migration. Tissue injury and repair initiates the inflammatory
cascade, leading to the classical picture of NEC [6,35,36].
The limited de novo arginine production capacity in
neonates makes arginine an essential amino acid in early
life. In these two studies, L-arginine in premature infants
was supplemented with the intention of increasing NO
synthesis with the rationale that NO’s role as a vasodila-
tor would be protective to the gut through prevention ofTable 3 Secondary outcomes
Name of study Outcome
Amin et al. [30] RDS
Polycarpou et al. [31] RDS
Amin et al. [30] IVH grade III and IV
Polycarpou et al. [31] IVH grade III and IV
Amin et al. [30] Total PDA
Amin et al. [30] PDA treated with indomethacin
Amin et al. [30] PDA treated surgically
Amin et al. [30] Sepsis
Amin et al. [30] Hypotension after 24 h age
Values are presented as No. (%) unless otherwise indicated.
Abbreviations: IVH Intraventricular hemorrhage, ND No data, PDA Patent ductus arteischemic injury [30,31]. Interestingly, while only a frac-
tion of arginine metabolism enters the NOS pathway to
produce NO, it appears as though this small proportion
of the overall body arginine lends substantially to the
prevention of intestinal ischemia, likely via regulating
mesenteric blood flow.
The strengths of this updated systematic review are
the inclusion of a recent trial, increased power based on
sample size, and detailed subgroup analyses. The current
analysis provides evidence in the favor of prophylactic
use of L-arginine in premature infants to prevent NEC.
This review included only two small RCTs with a small
number of subjects. The limitation of the two included
studies was overcome by conducting this systematic re-
view. Additionally, one of the two studies was under-
powered. Despite this, statistically significant reductions
in the incidence of stage II and III NEC, as well as all
stages of NEC, were noted, with p-values of less than
0.05.
Conclusions
Our study revealed that L-arginine has a significant role
in reducing the incidence of medical and surgical NEC in
modern NICUs without impact on long-term neurodeve-
lopmental outcomes at 36 months of corrected age.
However, in the absence of large multi-centre, random-
ized, controlled trials, the use of supplemental L-arginineArginine group Placebo/control RR, 95% CI
48/75 (64) 51/77 (66) 0.97 (0.77-1.22)
31/40 (77.5) 35/43 (81.4) 0.95 (0.76-1.19)
3/75 (4) 3/77 (4) 1.03 (0.21-4.93)
9/40 (22.5) 12 (27.9) 0.81 (0.38-1.71)
46/75 (61) 45/77 (58) 1.13 (0.59-2.16)
33/75 (44) 38/77 (49) 0.89 (0.63-1.25)
15/75 (20) 13/77 (17) 1.18 (0.61-2.32)
9/75 (12) 11/77 (14) 0.84 (0.37-1.91)
8/75 (11) 8/77 (10) 1.03 (0.37-2.90)
riosus, RDS Respiratory distress syndrome.
Figure 7 Neurodevelopmental outcomes at 36 months corrected age.
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term neonates has not become routine practice.
Implications for practice
Given the significant morbidity and mortality associated
with medical and surgical NEC, a preventative measure
to reduce the incidence and severity of the disease would
be a welcomed addition to routine NICU care. Consider-
ing the findings of this study, particularly the NNT of 9
for stages II and III NEC and the NNT of 5 for all stages
of NEC, an intriguing role for L-arginine supplementa-
tion continues to gain support.
Future research
With the addition of the results of this study to the lit-
erature, L-arginine supplementation continues to gain
support and will become the basis for a future largeclinical trial. We believe that large multi-centre RCTs
are needed before such supplementation can become
common practice.
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